FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 11/2022”. The Monitor is a month-to-month revealed overview of enterprise capital tendencies within the European Life Sciences sector.
As of the tip of November 2022 we determine the next present VC tendencies in Europe:
- In 2022, total Life Sciences funding has reached EUR 9,182m to this point
- Prime 5 Offers exceed EUR 140m every, largest transaction amounted to EUR 500m in Doctolib (France)
- Bpifrance (France) dominates the Prime 5 Buyers (by deal quantity), adopted by Eurazeo (France) and Common Atlantic (United States)
- Biotech acquired 44% of the overall funding quantity, (no change in comparison with the earlier month)
- Oncology nonetheless dominates as the highest indication in Biotechnology
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink